Psychotropic medication utilization in a child and adolescent mental health service

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 3, 2006, Pages 273-285

  Dean, Angela J ^a,b   McDermott, Brett M ^a   Marshall, Robert T ^b  

^a Kids in Mind Research   (Australia)

^b Mater Health Services   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CITALOPRAM; CLONIDINE; DEXAMPHETAMINE; DIAZEPINE DERIVATIVE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; METHYLPHENIDATE; MIRTAZAPINE; MOOD STABILIZER; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ADOLESCENT; CHILD; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG ABUSE; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL HEALTH SERVICE; MOOD DISORDER; OUTPATIENT; POLYPHARMACY; RETROSPECTIVE STUDY; REVIEW; SUICIDAL BEHAVIOR; TREATMENT INDICATION;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; ADULT; AUSTRALIA; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; POLYPHARMACY; PSYCHOTROPIC DRUGS;

EID: 33745127370     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.273     Document Type: Review

References (40)

1. Berbatis CG, Sunderland VB, Bulsara M: Licit psychostimulant consumption in Australia, 1984-2000: International and jurisdictional comparison. Med J Aust 177:539-543, 2002.
2. Bramble D: Annotation: The use of psychotropic medications in children: A British view. J Child Psychol Psychiatry 44:169-179, 2003.
3. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT: Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 14:372-394, 2004.
4. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA: New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 158:753-759, 2004.
5. Cuenca PJ, Holt KR, Hoefle JD: Seizure secondary to citalopram overdose. J Emerg Med 26:177-181, 2004.
6. Dalfen AK, Stewart DE: Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors? Can J Psychiatry 46:258-263, 2001.
7. Duffy FF, Narrow WE, Rae DS, West JC, Zarin DA, Rubio-Stipec M, Pincus HA, Regier DA: Concomitant pharmacotherapy among youths treated in routine psychiatric practice. J Child Adolesc Psychopharmacol 15:12-25, 2005.
8. Efron D, Hiscock H, Sewell JR, Cranswick NE, Vance AL, Tyl Y, Luk ES: Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 111:372-375, 2003.
9. Greenhill LL, Vitiello B, Abikoff H, Levine J, March JS, Riddle MA, Capasso L, Cooper TB, Davies M, Fisher P, Findling RL, Fried J, Labellarte MJ, McCracken JT, McMahon D, Robinson J, Skrobala A, Scahill L, Varipatis E, Walkup JT, Zito JM: Developing methodologies for monitoring long-term safety of psychotropic medications in children: Report on the NIMH conference, September 25, 2000. J Am Acad Child Adolesc Psychiatry 42:651-655, 2003.
10. Grohmann R, Engel RR, Geissler KH, Ruther E: Psychotropic drug use in psychiatric inpatients: Recent trends and changes over time data from the AMSP study. Pharmacopsychiatry 37 (Suppl 1):S27-S38, 2004.
11. Hawton K, Hall S, Simkin S, Bale L, Bond A, Codd S, Stewart A: Deliberate self-harm in adolescents: A study of characteristics and trends in Oxford, 1990-2000. J Child Psychol Psychiatry 44:1191-1198, 2003.
12. Hemeryck A, Belpaire FM: Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update. Curr Drug Metab 3:13-37, 2002.
13. Holden C: Psychopharmacology. FDA weighs suicide risk in children on antidepressants. Science 303:745, 2004.
14. Isbister GK, Bowe SJ, Dawson A, Whyte IM: Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 42:277-285, 2004.
15. Jensen PS, Edelman A, Nemeroff R: Pediatric pharmacoepidemiology: Who is prescribing and for whom, how, and why? In: Pediatric Psychopharmacology: Principles and Practice. Edited by Martin A, Scahill L, Charney DS, Leckman JF. New York, Oxford University Press, 2003, pp 701-711.
16. Kaplan SL, Busner J: Prescribing practices of inpatient child psychiatrists under three auspices of care. J Child Adolesc Psychopharmacol 7:275-286, 1997.
17. Kluger J: Medicating young minds. Time 162:48, 2003.
18. Lekhwani M, Nair C, Nikhinson I, Ambrosini PJ: Psychotropic prescription practices in child psychiatric inpatients 9 years old and younger. J Child Adolesc Psychopharmacol 14:95-103, 2004.
19. Mant A, Rendle VA, Hall WD, Mitchell PB, Montgomery WS, McManus PR, Hickie IB: Making new choices about antidepressants in Australia: The long view, 1975-2002. Med J Aust 181:S21-S24, 2004.
20. Mazur JE, Doty JD, Krygiel AS: Fatality related to a 30-g venlafaxine overdose. Pharmacotherapy 23:1668-1672, 2003.
21. McDermott BM, McKelvey R, Roberts L, Davies L: Severity of children's psychopathology and impairment and its relationship to treatment setting. Psychiatr Serv 53:57-62, 2002.
22. Najjar F, Welch C, Grapentine WL, Sachs H, Siniscalchi J, Price LH: Trends in psychotropic drug use in a child psychiatric hospital from 1991 to 1998. J Child Adolesc Psychopharmacol 14:87-93, 2004.
23. Olfson M, Marcus SC, Weissman MM, Jensen PS: National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 41:514-521, 2002.
24. Ostrom M, Eriksson A, Thorson J, Spigset O: Fatal overdose with citalopram. Lancet 348:339-340, 1996.
25. Pappadopulos EA, Tate Guelzow B, Wong C, Ortega M, Jensen PS: A review of the growing evidence base for pediatric psychopharmacology. Child Adolesc Psychiatr Clin North Am 13:817-855, vi, 2004.
26. Pearson G: Revisiting medication for kids. Addressing Barriers to Learning. 1:1996.
27. Phillips T, Salmon G, James AC: Prescribing practices in child and adolescent psychiatry: Change over time, 1993-2000. Child Adolesc Ment Health 8:23-28, 2003.
28. Pincus HA, Tanielian TL, Marcus SC, Olfson M, Zarin DA, Thompson J, Magno Zito J: Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA 279:526-531, 1998.
29. Safer DJ, Krager JM: Effect of a media blitz and a threatened lawsuit on stimulant treatment. JAMA 268:1004-1007, 1992.
30. Safer DJ, Zito JM, DosReis S: Concomitant psychotropic medication for youths. Am J Psychiatry 160:438-449, 2003.
31. Sawyer MG, Arney FM, Baghurst PA, Clark JJ, Graetz BW, Kosky RJ, Nurcombe B, Patton GC, Prior MR, Raphael B, Rey JM, Whaites LC, Zubrick SR: The mental health of young people in Australia: Key findings from the child and adolescent component of the national survey of mental health and well-being. Aust N Z J Psychiatry 35:806-814, 2001.
32. Shah R, Uren Z, Baker A, Majeed A: Deaths from antidepressants in England and Wales, 1993-1997: Analysis of a new national database. Psychol Med 31:1203-1210, 2001.
33. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133-145, 2004.
34. Simeon JG, Wiggins DM, Williams E: Worldwide use of psychotropic drugs in child and adolescent psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 19:455-465, 1995.
35. Spencer T, Biederman J, Wilens T, Greene R: Attention-deficit/ hyeractivity disorder. In: Pediatric Psychopharmacology: Principles and Practice. Edited by Martin A, Scahill L, Charney DS, Leekman JF. New York, Oxford University Press, 2003, pp 477-465.
36. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E: Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 363:1341-1345, 2004.
37. Whyte IM, Dawson AH, Buckley NA: Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96:369-374, 2003.
38. Wolraich ML: Annotation: The use of psychotropic medications in children: An American view. J Child Psychol Psychiatry 44:159-168, 2003.
39. Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L, Soeken K, Boles M, Lynch F, Riddle MA: Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med 157:17-25, 2003.
40. Zito JM, Safer DJ, DosReis S, Gardner JF, Soeken K, Boles M, Lynch F: Rising prevalence of antidepressants among U.S. youths. Pediatrics 109:721-727, 2002.